Cytek Biosciences to participate in the Piper Sandler 36th Annual Healthcare Conference
Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program
Cytek Biosciences, Inc. (NASDAQ: CTKB) had its price target raised by analysts at Piper Sandler from $8.00 to $8.50. They now have an "overweight" rating on the stock.
Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter
Cytek Biosciences Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]